The Management of Hypertension: Vol.13
Published in June 1990
Book
Hardback
606 pages
978-0-444-81126-4 (ISBN)
Description
The past three decades have witnessed a veritable explosion in knowledge of high blood pressure and related cardiovascular phenomena. It revolves around two research tracks, one involving new physiologic and pathophysiologic mechanisms, the other the development of increasingly specific drugs to block homeostatic or pathogenic pressor mechanisms at specific points. It has become clear that all hypertension is not alike. It can no longer be analyzed and treated as if it were a single pathologic or clinical syndrome. This means that those millions of people the world over who have in common high blood pressure do not all have the same disorder. In this context, hypertension is a biophysical sign, for which there can be many different causes. It follows that there are differences in drug responsiveness according to these various biochemical characteristics. Thus it is appropriate for investigators and clinicians alike to consider human hypertension as a biophysical sign for which every resource should be mobilized to characterize its nuances in the individual patient. The goal in drug therapy is to select and verify the most effective and specific treatment for that individual.
The past three decades have witnessed a veritable explosion in knowledge of high blood pressure and related cardiovascular phenomena. It revolves around two research tracks, one involving new physiologic and pathophysiologic mechanisms, the other the development of increasingly specific drugs to block homeostatic or pathogenic pressor mechanisms at specific points. It has become clear that all hypertension is not alike. It can no longer be analyzed and treated as if it were a single pathologic or clinical syndrome. This means that those millions of people the world over who have in common high blood pressure do not all have the same disorder. In this context, hypertension is a biophysical sign, for which there can be many different causes. It follows that there are differences in drug responsiveness according to these various biochemical characteristics. Thus it is appropriate for investigators and clinicians alike to consider human hypertension as a biophysical sign for which every resource should be mobilized to characterize its nuances in the individual patient. The goal in drug therapy is to select and verify the most effective and specific treatment for that individual.
The past three decades have witnessed a veritable explosion in knowledge of high blood pressure and related cardiovascular phenomena. It revolves around two research tracks, one involving new physiologic and pathophysiologic mechanisms, the other the development of increasingly specific drugs to block homeostatic or pathogenic pressor mechanisms at specific points. It has become clear that all hypertension is not alike. It can no longer be analyzed and treated as if it were a single pathologic or clinical syndrome. This means that those millions of people the world over who have in common high blood pressure do not all have the same disorder. In this context, hypertension is a biophysical sign, for which there can be many different causes. It follows that there are differences in drug responsiveness according to these various biochemical characteristics. Thus it is appropriate for investigators and clinicians alike to consider human hypertension as a biophysical sign for which every resource should be mobilized to characterize its nuances in the individual patient. The goal in drug therapy is to select and verify the most effective and specific treatment for that individual.
More details
Series
Language
English
Place of publication
Oxford
United Kingdom
Publishing group
Elsevier Science & Technology
Target group
College/higher education
Professional and scholarly
Dimensions
Height: 230 mm
Weight
1310 gr
ISBN-13
978-0-444-81126-4 (9780444811264)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Content
Foreword. Introduction. I. The consequences of high blood pressure. 1. Cardiovascular risk: the impact of blood pressure and its correction (M.H. Alderman and P.R. Marantz). 2. What clinical trials have taught us (C.G. Isles et al). 3. Is there a hypertensive coronary-prone personality? (E.H. Johnson and S. Julius). 4. Ambulatory blood pressure monitoring and cardiovascular risk (M. Burnier et al). 5. Target-organ damage and planning therapy (H. Ibsen). II. The evaluation of the hypertensive patient. 6. Screening for curable hypertension (O.K. Andersson et al). 7. Renovascular hypertension: update on diagnosis and treatment (T.F. Luscher et al). 8. Hypertension and the adrenal cortex (C.R.W. Edwards). 9. Argument for a minimal evaluation of the hypertensive patient (N.M. Kaplan). 10. Blood pressure monitoring devices (T.G. Pickering). 11. Electrocardiographic and echocardiographic features in hypertension: their assessment, diagnostic and prognostic value (P. Bolli et al). III. Antihypertensive drug classes and practical use. 12. The diuretic dilemma (J.R. Cockcroft and C.T. Dollery). 13. Beta-blockers (G. Hausler et al). 14. Calcium antagonists for antihypertensive care (F.R. Buhler et al). 15. Treatment of hypertension with angiotensin-converting enzyme inhibitors as monotherapy (B. Waeber et al). 16. Direct-acting vasodilating agents (P. van Brummelen and C.J. Doorenbos). 17. a 1 -Adrenoceptor antagonists and sympatholytic drugs in the management of hypertension (R.F. Schafers and J.L. Reid). IV. Treatment strategies: why, when and how to treat? 18. Non-drug therapy: salt, weight, alcohol, exercise and tobacco (J.D. Swales). 19. The problem of salt restriction (F.O. Simpson). 20. Antihypertensive therapy and the lipid risk factor (Y. Goto and H. Tamachi). 21. Rationale for individualized therapies (J.H. Laragh). 22. Socioeconomic influences on treatment (T. Lang et al). 23. Measurement of quality of life in hypertension (A. Fletcher and C.J. Bulpitt). 24. Primary prevention, coronary flow reserve and antihypertensive therapy (F.R. Buhler and J.M. Cruickshank). 25. WHO/ISH guidelines and their implications (T. Strasser and L. Hansson). V. Special treatment situations. 26. Treatment of hypertension in renal disease (A.E.G. Raine and J.G.G. Ledingham). 27. Hypertension in the elderly (A. Amery et al). 28. Decision-making in childhood hypertension (B. Falkner and J. Tannenbaum). 29. Antihypertensive treatment in pregnancy (W.F. Lubbe). 30. Antihypertensive drugs and anesthesia (C. Prys-Roberts). 31. Hypertensive emergencies: mechanisms and treatment (A. Distler and E. Fritschka). Index.